RIP1 is a promising therapeutic target for neurodegenerative diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, as well as acute neurological conditions such as stroke and traumatic brain injuries [34, 35]. Here, RIPK1 is linked to amyotrophic lateral sclerosis.